Solutions for
albumin pasteurization

Compatible reusable parts are packaged in bags or loaded into closed canisters before steam sterilization. The process is developed around the complete load configuration to govern air removal, steam penetration, condensate management and drying. Once treated, the selected packaging or transfer system preserves the sterile state during unloading, movement and introduction into the aseptic processing environment.

For reusable parts that cannot withstand steam, low-temperature H₂O₂ sterilization provides an alternative route when supported by material, geometry and packaging compatibility. The complete configuration is evaluated to establish sterilant access, microbial reduction, aeration and residual removal. The treated load then follows a protected transfer route designed to preserve its required state up to the aseptic interface.

Bulk stoppers are washed and steam sterilized in one integrated process developed to control cleanliness, sterility and residual moisture. Following treatment, the closures are discharged directly into a sterile transfer tank. This eliminates intermediate bagging and creates the starting point for a closed route from stopper preparation to automated delivery at the isolator.

Washing and steam sterilization are integrated within one system to establish cleanliness and sterility through a coordinated process. This architecture reduces equipment interfaces, material movements and classified-space requirements while strengthening control between the two treatments. It is selected for compatible reusable loads when layout efficiency, operator protection or a more contained process route drives the transfer strategy.

RTU components and other pre-sterilized materials already contain a protected sterile product within sealed packaging. The low-temperature H₂O₂ process treats the external surfaces before introduction into the aseptic environment without reopening the package or altering its internal sterile state. Cycle development addresses packaging geometry, surface accessibility, load arrangement and aeration as part of the complete transfer configuration.

The automated manipulator connects treatment and point of use through controlled loading, unloading, movement and delivery operations. Depending on the selected route, it handles canisters, sterile tanks or treated materials and manages their interface with the isolator or filling line. Automation removes avoidable manual interventions precisely where exposure, repeated handling and open connections create the greatest vulnerability.

Validated washing removes process residues and establishes the required cleanliness state for reusable product-contact, machine and format parts. Cycle parameters, load configuration and mechanical action are developed around the materials and geometries involved, preparing every surface for the selected downstream treatment and preventing cleaning from becoming an uncontrolled variable within the aseptic-transfer route.

Small molecules continue to represent a major share of sterile pharmaceutical manufacturing worldwide. For heat-stable formulations, terminal sterilization remains the preferred sterility assurance approach because it allows the final packaged product to be sterilized after filling and closing.
Yet sterilizing liquids in closed containers is not simply a question of lethality. During heating and cooling, thermal expansion and vapor generation continuously change the pressure inside the container.

The rapid growth of biologics, nanoparticle-based medicines and Advanced Therapy Medicinal Products (ATMPs) is redefining the relationship between pharmaceutical formulations and primary packaging.
Interactions between proteins such as insulin, nanoparticles and container surfaces are well-recognised phenomena that can influence product stability, efficacy and patient safety. As these therapies become increasingly sensitive, material compatibility can no longer be considered an intrinsic property of the container alone.

When manufacturers seek to move away from EtO towards a method that reduces toxic-residue concerns and the potential burden on patients, workers and the environment, selecting an alternative sterilant is only the beginning.
This is particularly true for the low-temperature sterilization of RTU glass vials in their complete packaging configuration. The sterilant must pass through the outer transport box, multiple porous barriers and enclosed packaging interfaces before reaching the internal vial surfaces. The same structure must then release residual sterilant within an acceptable aeration time.